This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Geron Announces Senior Management Appointments

Geron Corporation (Nasdaq:GERN) today announced the appointments of Stephen Kelsey, M.D., to Executive Vice President, Head of Research & Development and Chief Medical Officer; Jane Lebkowski, Ph.D., to Senior Vice President and Geron’s Chief Scientific Officer; and Melissa Kelly Behrs to Senior Vice President, Strategic Portfolio Management. Drs. Kelsey and Lebkowski and Ms. Behrs will report to David Greenwood, Geron’s President and Chief Executive Officer.

“By appointing Dr. Kelsey, Dr. Lebkowski and Ms. Behrs to these roles with functional responsibilities across Geron’s programs, we leverage their accumulated expertise and distinctive capabilities to direct the science and clinical programs, and to integrate the strategic business plan,” said Mr. Greenwood. “Steve has a proven track record in clinical development and leadership of research programs and in this capacity will manage to meet our defined goals within defined timeframes. Under Jane’s leadership, the Geron team advanced hESC technology from initial discovery to a first product in the clinic, with every step being an inventive step. Geron was founded on innovative and excellent science, including telomerase and hESCs, leading to our products in the clinic today. We want to maintain this tradition internally and build on our external network of key thought leaders. Finally, it is imperative that a technology rich company like Geron maintains the product development focus with clearly defined strategies to progress products into and through clinical trials. Melissa has well demonstrated capabilities to provide this leadership.”

Dr. Kelsey joined Geron in 2009 as Executive Vice President and Chief Medical Officer, Oncology. Previously, he held senior positions at Genentech and Pharmacia (Sugen, Inc.), where he was responsible for a broad range of development programs spanning pre-Phase 1 through marketed products. Dr. Kelsey held positions as a clinician and researcher in hematology/oncology at St. Bartholomews and the Royal London School of Medicine and Dentistry. He earned his M.D. in the U.K. at the University of Birmingham.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,069.49 -1.73 -0.01%
S&P 500 1,976.91 -0.89 -0.04%
NASDAQ 4,498.6730 -7.1790 -0.16%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs